ZA200707953B - Methods and compositions for modulating hyperstabilized c-met - Google Patents

Methods and compositions for modulating hyperstabilized c-met

Info

Publication number
ZA200707953B
ZA200707953B ZA200707953A ZA200707953A ZA200707953B ZA 200707953 B ZA200707953 B ZA 200707953B ZA 200707953 A ZA200707953 A ZA 200707953A ZA 200707953 A ZA200707953 A ZA 200707953A ZA 200707953 B ZA200707953 B ZA 200707953B
Authority
ZA
South Africa
Prior art keywords
hyperstabilized
modulating
met
compositions
methods
Prior art date
Application number
ZA200707953A
Other languages
English (en)
Inventor
Kong-Beltran Monica
Dineli M Wickramasinghe
Original Assignee
Genenthech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200707953(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genenthech Inc filed Critical Genenthech Inc
Publication of ZA200707953B publication Critical patent/ZA200707953B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200707953A 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met ZA200707953B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25

Publications (1)

Publication Number Publication Date
ZA200707953B true ZA200707953B (en) 2009-06-24

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707953A ZA200707953B (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Country Status (18)

Country Link
US (2) US7615529B2 (zh)
EP (1) EP1868648B1 (zh)
JP (2) JP2008535821A (zh)
KR (1) KR20080000613A (zh)
CN (1) CN101184506B (zh)
AU (1) AU2006229989B2 (zh)
BR (1) BRPI0611468A2 (zh)
CA (1) CA2599988A1 (zh)
ES (1) ES2539790T3 (zh)
HK (1) HK1109075A1 (zh)
IL (1) IL185708A (zh)
MX (1) MX2007011652A (zh)
NO (1) NO20075412L (zh)
NZ (1) NZ561211A (zh)
RU (1) RU2404193C2 (zh)
SG (1) SG159547A1 (zh)
WO (1) WO2006104911A2 (zh)
ZA (1) ZA200707953B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2404193C2 (ru) * 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта
CA2716851A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
CN102164961B (zh) * 2008-10-01 2014-04-16 安进研发（慕尼黑）股份有限公司 种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2417164A1 (en) * 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
CN102378768A (zh) * 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
KR101736076B1 (ko) 2009-04-20 2017-05-16 옥스포드 바이오테라퓨틱스 리미티드 카드헤린-１７에 특이적인 항체
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
BR112012010153B1 (pt) * 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
AU2011318574B2 (en) * 2010-10-20 2016-03-03 Oxford Biotherapeutics Ltd. Antibodies
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
RU2014124842A (ru) * 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
BR112015021462A2 (pt) 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
CA2941687A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
CA3035932A1 (en) 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
BR112021000620A2 (pt) 2018-07-15 2021-04-20 Enochian BioPharma, Inc. métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer
JOP20210233A1 (ar) 2019-02-26 2023-01-30 Janssen Biotech Inc علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE69739276D1 (de) 1996-04-05 2009-04-09 Antonio Giordano Methoden zur diagnose und prognose von krebs
IL127558A0 (en) * 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
WO2003088808A2 (en) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
EP2093570A1 (en) * 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2008507252A (ja) * 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
ZA200604864B (en) 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
RU2404193C2 (ru) 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта
JP2008533991A (ja) * 2005-03-25 2008-08-28 ジェネンテック・インコーポレーテッド 肺癌におけるｃ−ｍｅｔ突然変異

Also Published As

Publication number Publication date
CN101184506B (zh) 2013-07-17
HK1109075A1 (zh) 2008-05-30
NZ561211A (en) 2011-03-31
US20060270594A1 (en) 2006-11-30
RU2007139452A (ru) 2009-04-27
JP2008535821A (ja) 2008-09-04
US8536118B2 (en) 2013-09-17
NO20075412L (no) 2007-12-21
CA2599988A1 (en) 2006-10-05
US20100028337A1 (en) 2010-02-04
WO2006104911A3 (en) 2007-02-22
US7615529B2 (en) 2009-11-10
MX2007011652A (es) 2007-11-14
AU2006229989A1 (en) 2006-10-05
CN101184506A (zh) 2008-05-21
ES2539790T3 (es) 2015-07-06
JP2012232979A (ja) 2012-11-29
BRPI0611468A2 (pt) 2010-09-08
RU2404193C2 (ru) 2010-11-20
EP1868648B1 (en) 2015-04-15
WO2006104911A2 (en) 2006-10-05
EP1868648A2 (en) 2007-12-26
IL185708A0 (en) 2008-01-06
AU2006229989B2 (en) 2012-02-02
SG159547A1 (en) 2010-03-30
KR20080000613A (ko) 2008-01-02
IL185708A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
ZA200707953B (en) Methods and compositions for modulating hyperstabilized c-met
EP1895838A4 (en) COMPOSITIONS AND METHODS
EP1930012A4 (en) COMPOSITION CONTAINING A CELLO-OLIGOSACCHARIDE
GB0522658D0 (en) Composition
HK1165444A1 (zh) 用於調整止血的組合物及方法
EP1843734A4 (en) COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0519164D0 (en) Composition
GB0506044D0 (en) Composition
GB0508250D0 (en) Composition
EP1847249A4 (en) hair dye
GB0507167D0 (en) Composition
IL185753A0 (en) Methods and compositions for modulating vascular integrity
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0501348D0 (en) Compositions and methods
GB0502341D0 (en) Composition
GB0513641D0 (en) Anti-egeing composition
EP1809761A4 (en) COMPOSITIONS AND METHODS FOR MODULATING DHR96
EP1924257A4 (en) STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR
GB0510286D0 (en) Composition
GB0525968D0 (en) Compositions and methods
GB0511497D0 (en) Composition
GB0515477D0 (en) Composition